Clinical trials · Indiana
Liver Diseases clinical trials in Indiana
We’re tracking 19 recruiting liver diseases studies with a site in Indiana — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Indiana
- NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Indianapolis, IndianaAges 18–70 - NCT07191886Recruiting
Managing liver disease: what matters to you?
This study asks people with liver disease about their needs and concerns during regular clinic visits. Your answers may help doctors improve care for others.
Indianapolis, IndianaAges 18 years+ - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Indianapolis, IndianaAges 18 years+ - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Indianapolis, IndianaAges 18–75 - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT07165028RecruitingPhase 3
Study of new drugs for fatty liver with scarring
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Indianapolis, IndianaAges 18 years+ - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Indianapolis, IndianaAges 18–75 - NCT03228290Recruiting
Liver transplant care study using patient function check
This study looks at how people with liver disease function day to day, especially around liver transplant care. It may help improve how doctors assess readiness and recovery needs.
Indianapolis, IndianaAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Hammond, IndianaAges 18 years+ - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Hammond, IndianaAges 18 years+ - NCT07060638RecruitingPhase 2
Combination therapy for severe alcoholic hepatitis
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
Indianapolis, IndianaAges 18–70 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Hammond, IndianaAges 18–80 - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Indianapolis, IndianaAges 2–25 - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Newburgh, IndianaAges 18–75 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Indianapolis, IndianaAges 18–75 - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Indianapolis, IndianaAges Any age - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Indianapolis, IndianaAges 18 years+ - NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Indianapolis, IndianaAges 2 years+
Liver Diseases trials by city in Indiana
Where these studies are running in Indiana
Institutions with a site for the recruiting liver diseases studies listed above.
- Indiana University School of Medicine · 10 studies
- Digestive Research Alliance of Michiana · 3 studies
- ASHA Clinical Research · 2 studies
- Riley Hospital for Children · 2 studies
- Zydus · 2 studies
- 89bio Clinical Study Site
- Deaconess Clinic - Gateway Health Center
- Deaconess Clinic - GI Specialty Center
What taking part in a liver diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Liver Diseases trials in other states
Common questions
- Are there liver diseases clinical trials in Indiana?
- Yes. We're currently tracking 19 recruiting liver diseases studies with a site in Indiana, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a liver diseases study in Indiana?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Indiana to take part?
- Not necessarily. These studies have a site in Indiana, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a liver diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New liver diseases studies open in Indiana regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.